The Midlands Therapeutics Review and Advisory Committee has published reviews of pioglitazone, rosiglitazone and exenatide.
The review of pioglitazone suggests that this drug is suitable for prescribing in primary care but only after metformin and sulphonylureas.
The review of rosiglitazone suggests that this drug should not be initiated in primary care. It is also recommended that patients who are well controlled and stable on treatment can be continued until further data become available to aid decision making.
The review of exenatide suggests that this drug is suitable for initiation in secondary care and once the patient is stabilised it can be continued in primary care.
Action: Clinicians who treat diabetes in primary or secondary care will find these product reviews to be a useful summary of the currently available evidence.
|« MHRA advice on rimonabant||HPA give flood health advice »|